RNatives
RNatives is a biotechnology platform company specializing in RNA-based gene regulating therapies, focusing on upregulating endogenous VEGFA gene to treat cardiovascular diseases such as myocardial ischemia and peripheral artery disease. Their proprietary platform technology leverages novel biology of nuclear microRNAs to modulate gene expression, enabling neovascularization and tissue recovery. The company operates a dedicated molecular biology laboratory and BSL-2 clean room for discovery and development of RNA activation drugs, with a pipeline driven by extensive academic research and in vivo validation. RNatives offers an AI-assisted discovery platform for co-development with pharmaceutical partners, aiming to revolutionize medicine through innovative gene therapy solutions. Their business model includes platform technology co-development and licensing with pharma partners, supported by a team of experienced scientists and executives.
RNatives
RNatives is a biotechnology platform company specializing in RNA-based gene regulating therapies, focusing on upregulating endogenous VEGFA gene to treat cardiovascular diseases such as myocardial ischemia and peripheral artery disease. Their proprietary platform technology leverages novel biology of nuclear microRNAs to modulate gene expression, enabling neovascularization and tissue recovery. The company operates a dedicated molecular biology laboratory and BSL-2 clean room for discovery and development of RNA activation drugs, with a pipeline driven by extensive academic research and in vivo validation. RNatives offers an AI-assisted discovery platform for co-development with pharmaceutical partners, aiming to revolutionize medicine through innovative gene therapy solutions. Their business model includes platform technology co-development and licensing with pharma partners, supported by a team of experienced scientists and executives.